{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:47:30Z","timestamp":1788050850472,"version":"build-2784847793"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003356","name":"Gazi University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003356","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>The International League of Associations for Rheumatology (ILAR) juvenile idiopathic arthritis (JIA) classification was revisited by the Pediatric Rheumatology International Trials Organization (PRINTO) in 2018. Classifications should establish uniform groups to assist physicians in providing optimal care. Therefore, we evaluated changes proposed by PRINTO to highlight their impact on forming consistent groups regarding uveitis and treatment responses, particularly focusing on early-onset anti-nuclear antibody (ANA)-positive JIA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Pediatric patients diagnosed with JIA according to ILAR and PRINTO classification, with a minimum of 1-year of follow-up, were enrolled, excluding those meeting the exclusion criteria for both the oligoarticular JIA and the early-onset ANA-positive JIA groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among the 139 enrolled patients, 110 (79.1%) had oligoarticular JIA, while 15 (10.8%) had early-onset ANA-positive JIA. The below-age-5 criterion demonstrated the strongest association with uveitis, while the below-age-7 provided similar associations without substantial exclusions (odds ratio (OR) 8.62 [2.50\u201329.81] vs 7.45 [2.37\u201326.66]). Patients with a single ANA positivity at a titer\u2009\u2265\u20091\/160 and age of onset below 7 had a notably higher risk of new-onset uveitis and biologic DMARD requirement (OR 7.95 [2.37\u201326.66] and 3.6 [1.42\u20139.09], respectively).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The inclusion of age of disease onset and ANA positivity with a titer\u2009\u2265\u20091\/160 has enhanced uniformity in uveitis risk and treatment response, including failure of conventional synthetic DMARDs. Additionally, a single ANA positivity at a\u2009\u2265\u20091\/160 titer rather than requiring two instances yields similar consistency. However, the joint count criteria failed to form consistent groups. PRINTO\u2019s classification places a significant proportion of patients into the \u201cother JIA\u201d group, necessitating further classification for improved clinical utility.\n<jats:table-wrap>\n                <jats:table>\n                  <jats:tbody>\n                    <jats:tr>\n                      <jats:td align=\"left\" colspan=\"2\">\n                        <jats:bold>Key Points<\/jats:bold>\u2022<jats:italic>Inclusion of age and ANA positivity criteria increased uniformity among the subgroups<\/jats:italic>.\u2022<jats:italic>Single ANA positivity at a\u2009\u2265\u20091\/160 titer can be sufficient instead of twice<\/jats:italic>.\u2022<jats:italic>Early utilization of bDMARDs may be beneficial for early-onset ANA-positive JIA group<\/jats:italic>.\u2022<jats:italic>PRINTO classification must further classify the \u201cother JIA\u201d before being implemented in clinical practice<\/jats:italic>.<\/jats:td>\n                    <\/jats:tr>\n                  <\/jats:tbody>\n                <\/jats:table>\n              <\/jats:table-wrap>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10067-025-07340-z","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T05:48:25Z","timestamp":1738216105000},"page":"1307-1316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of ILAR and PRINTO classifications for juvenile idiopathic arthritis: oligoarticular JIA vs early-onset ANA-positive JIA"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4268-8603","authenticated-orcid":false,"given":"Batuhan","family":"K\u00fc\u00e7\u00fckali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6901-9944","authenticated-orcid":false,"given":"\u00c7isem","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3435-4336","authenticated-orcid":false,"given":"Bu\u011fra Taygun","family":"G\u00fclle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4823-2076","authenticated-orcid":false,"given":"Deniz","family":"Gezgin Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6530-9672","authenticated-orcid":false,"given":"Sevcan A.","family":"Bakkalo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"issue":"2","key":"7340_CR1","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390\u2013392","journal-title":"J Rheumatol"},{"issue":"10","key":"7340_CR2","first-page":"1991","volume":"25","author":"RE Petty","year":"1998","unstructured":"Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P et al (1998) Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 25(10):1991\u20131994","journal-title":"J Rheumatol"},{"issue":"6","key":"7340_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/acr.23870","volume":"71","author":"S Ringold","year":"2019","unstructured":"Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML et al (2019) 2019 American College of Rheumatology\/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res (Hoboken) 71(6):717\u2013734","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"7340_CR4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/art.42037","volume":"74","author":"KB Onel","year":"2022","unstructured":"Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST et al (2022) 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis & Rheumatology 74(4):553\u2013569","journal-title":"Arthritis & Rheumatology"},{"issue":"9","key":"7340_CR5","first-page":"1900","volume":"30","author":"A Martini","year":"2003","unstructured":"Martini A (2003) Are the number of joints involved or the presence of psoriasis still useful tools to identify homogeneous disease entities in juvenile idiopathic arthritis? J Rheumatol 30(9):1900\u20131903","journal-title":"J Rheumatol"},{"issue":"9","key":"7340_CR6","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1136\/annrheumdis-2012-201388","volume":"71","author":"A Martini","year":"2012","unstructured":"Martini A (2012) It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Ann Rheum Dis 71(9):1437\u20131439","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"7340_CR7","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1002\/art.22173","volume":"54","author":"ML Stoll","year":"2006","unstructured":"Stoll ML, Zurakowski D, Nigrovic LE, Nichols DP, Sundel RP, Nigrovic PA (2006) Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum 54(11):3564\u20133572","journal-title":"Arthritis Rheum"},{"issue":"3","key":"7340_CR8","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/art.20945","volume":"52","author":"A Ravelli","year":"2005","unstructured":"Ravelli A, Felici E, Magni-Manzoni S, Pistorio A, Novarini C, Bozzola E et al (2005) Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum 52(3):826\u2013832","journal-title":"Arthritis Rheum"},{"issue":"1","key":"7340_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12969-023-00869-w","volume":"21","author":"F Zulian","year":"2023","unstructured":"Zulian F, Pierobon B, Zannin ME, Politi C, Vittadello F, Meneghel A et al (2023) Monoarticular juvenile idiopathic arthritis as a distinct clinical entity a proof-of-concept study. Pediatr Rheumatol 21(1):81","journal-title":"Pediatr Rheumatol"},{"issue":"1","key":"7340_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/art.30076","volume":"63","author":"A Ravelli","year":"2011","unstructured":"Ravelli A, Varnier GC, Oliveira S, Castell E, Arguedas O, Magnani A et al (2011) Antinuclear antibody\u2013positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis Rheum 63(1):267\u2013275","journal-title":"Arthritis Rheum"},{"issue":"11","key":"7340_CR11","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1002\/art.27657","volume":"62","author":"MG Barnes","year":"2010","unstructured":"Barnes MG, Grom AA, Thompson SD, Griffin TA, Luyrink LK, Colbert RA et al (2010) Biologic similarities based on age at onset in oligoarticular and polyarticular subtypes of juvenile idiopathic arthritis. Arthritis Rheum 62(11):3249\u20133258","journal-title":"Arthritis Rheum"},{"issue":"3","key":"7340_CR12","doi-asserted-by":"publisher","first-page":"e002901","DOI":"10.1136\/rmdopen-2022-002901","volume":"9","author":"C Tom\u00e9","year":"2023","unstructured":"Tom\u00e9 C, Oliveira-Ramos F, Campanilho-Marques R, Mour\u00e3o AF, Sousa S, Marques C et al (2023) Children with extended oligoarticular and polyarticular juvenile idiopathic arthritis have alterations in B and T follicular cell subsets in peripheral blood and a cytokine profile sustaining B cell activation. RMD Open 9(3):e002901","journal-title":"RMD Open"},{"issue":"2","key":"7340_CR13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3899\/jrheum.180168","volume":"46","author":"A Martini","year":"2019","unstructured":"Martini A, Ravelli A, Avcin T, Beresford MW, Burgos-Vargas R, Cuttica R et al (2019) Toward new classification criteria for juvenile idiopathic arthritis: first steps Pediatric Rheumatology International Trials Organization International Consensus. J Rheumatol 46(2):190\u2013197","journal-title":"J Rheumatol"},{"issue":"4","key":"7340_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.20460","volume":"63","author":"T Beukelman","year":"2011","unstructured":"Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM et al (2011) 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 63(4):465\u2013482","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"7340_CR15","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/acr.23871","volume":"71","author":"ST Angeles-Han","year":"2019","unstructured":"Angeles-Han ST, Ringold S, Beukelman T, Lovell D, Cuello CA, Becker ML et al (2019) 2019 American College of Rheumatology\/Arthritis Foundation guideline for the screening, monitoring and treatment of juvenile idiopathic arthritis\u2013associated uveitis. Arthritis Care Res 71(6):703\u2013716","journal-title":"Arthritis Care Res"},{"key":"7340_CR16","doi-asserted-by":"crossref","unstructured":"Group SoUNW. 2005 Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 140 3 509\u201316","DOI":"10.1016\/j.ajo.2005.03.057"},{"issue":"5","key":"7340_CR17","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","volume":"61","author":"A Consolaro","year":"2009","unstructured":"Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G et al (2009) Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 61(5):658\u2013666","journal-title":"Arthritis Rheum"},{"issue":"1","key":"7340_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12969-016-0085-5","volume":"14","author":"A Consolaro","year":"2016","unstructured":"Consolaro A, Giancane G, Schiappapietra B, Davi S, Calandra S, Lanni S et al (2016) Clinical outcome measures in juvenile idiopathic arthritis. Pediatr Rheumatol Online J 14(1):23","journal-title":"Pediatr Rheumatol Online J"},{"issue":"9","key":"7340_CR19","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/art.1780400909","volume":"40","author":"EM Tan","year":"1997","unstructured":"Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ et al (1997) Range of antinuclear antibodies in \u201chealthy\u201d individuals. Arthritis Rheum 40(9):1601\u20131611","journal-title":"Arthritis Rheum"},{"key":"7340_CR20","doi-asserted-by":"crossref","unstructured":"Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K, German Uveitis in Childhood Study G. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford). 2007;46(6):1015-9","DOI":"10.1093\/rheumatology\/kem053"},{"key":"7340_CR21","doi-asserted-by":"publisher","first-page":"100145","DOI":"10.1016\/j.jtauto.2022.100145","volume":"5","author":"LEC Andrade","year":"2022","unstructured":"Andrade LEC, Damoiseaux J, Vergani D, Fritzler MJ (2022) Antinuclear antibodies (ANA) as a criterion for classification and diagnosis of systemic autoimmune diseases. J Transl Autoimmun 5:100145","journal-title":"J Transl Autoimmun"},{"issue":"2","key":"7340_CR22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/art.22381","volume":"56","author":"RK Saurenmann","year":"2007","unstructured":"Saurenmann RK, Levin AV, Feldman BM, Rose JB, Laxer RM, Schneider R et al (2007) Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum 56(2):647\u2013657","journal-title":"Arthritis Rheum"},{"issue":"11","key":"7340_CR23","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1002\/acr.23783","volume":"71","author":"JJY Lee","year":"2019","unstructured":"Lee JJY, Duffy CM, Guzman J, Oen K, Barrowman N, Rosenberg AM et al (2019) Prospective determination of the incidence and risk factors of new-onset uveitis in juvenile idiopathic arthritis: the research in arthritis in Canadian children emphasizing outcomes cohort. Arthritis Care Res (Hoboken) 71(11):1436\u20131443","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"7340_CR24","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ophtha.2020.08.024","volume":"128","author":"V Rypdal","year":"2021","unstructured":"Rypdal V, Glerup M, Songstad NT, Bertelsen G, Christoffersen T, Arnstad ED et al (2021) Uveitis in juvenile idiopathic arthritis: 18-year outcome in the population-based Nordic cohort study. Ophthalmology 128(4):598\u2013608","journal-title":"Ophthalmology"},{"issue":"4","key":"7340_CR25","first-page":"183","volume":"13","author":"Y Niwa","year":"1984","unstructured":"Niwa Y, Sakane T, Kanoh T, Shichijo S, Wiederhold MD, Yokoyama MM (1984) Transient autoantibodies with elevated complement levels in common viral diseases. J Clin Lab Immunol 13(4):183\u2013188","journal-title":"J Clin Lab Immunol"},{"issue":"6","key":"7340_CR26","first-page":"892","volume":"95","author":"PMG Deane","year":"1995","unstructured":"Deane PMG, Liard G, Siegel DM, Baum J (1995) The outcome of children referred to a pediatric rheumatology clinic with a positive antinuclear antibody-test but without an autoimmune-disease. Pediatrics 95(6):892\u2013895","journal-title":"Pediatrics"},{"issue":"6","key":"7340_CR27","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1093\/rheumatology\/keaa733","volume":"60","author":"JW van Straalen","year":"2021","unstructured":"van Straalen JW, Giancane G, Amazrhar Y, Tzaribachev N, Lazar C, Uziel Y et al (2021) A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 60(6):2896\u20132905","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"7340_CR28","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ncprheum0708","volume":"4","author":"A-B Mongey","year":"2008","unstructured":"Mongey A-B, Hess EV (2008) Drug insight: autoimmune effects of medications\u2014what\u2019s new? Nat Clin Pract Rheumatol 4(3):136\u2013144","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"1","key":"7340_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12969-016-0078-4","volume":"14","author":"R Donn","year":"2016","unstructured":"Donn R, De Leonibus C, Meyer S, Stevens A (2016) Network analysis and juvenile idiopathic arthritis (JIA): a new horizon for the understanding of disease pathogenesis and therapeutic target identification. Pediatr Rheumatol Online J 14(1):40","journal-title":"Pediatr Rheumatol Online J"},{"key":"7340_CR30","doi-asserted-by":"publisher","first-page":"108484","DOI":"10.1016\/j.clim.2020.108484","volume":"217","author":"J Fischer","year":"2020","unstructured":"Fischer J, Dirks J, Haase G, Holl-Wieden A, Hofmann C, Girschick H et al (2020) IL-21(+) CD4(+) T helper cells co-expressing IFN-gamma and TNF-alpha accumulate in the joints of antinuclear antibody positive patients with juvenile idiopathic arthritis. Clin Immunol 217:108484","journal-title":"Clin Immunol"},{"key":"7340_CR31","doi-asserted-by":"crossref","unstructured":"De Lucia O, Ravagnani V, Pregnolato F, Hila A, Pontikaki I, Gattinara M, et al. 2018 Baseline ultrasound examination as possible predictor of relapse in patients affected by juvenile idiopathic arthritis (JIA). Ann Rheum Dis. annrheumdis-2017\u2013211696","DOI":"10.1136\/annrheumdis-2017-211696"},{"key":"7340_CR32","doi-asserted-by":"crossref","unstructured":"Miotto e Silva VB, Mitraud SdAV, Furtado RNV, Natour J, Len CA, Terreri MTdSeLRA. Patients with juvenile idiopathic arthritis in clinical remission with positive power Doppler signal in joint ultrasonography have an increased rate of clinical flare: a prospective study. Pediatric Rheumatology. 2017 15:1\u20139","DOI":"10.1186\/s12969-017-0208-7"},{"issue":"9783","key":"7340_CR33","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","volume":"377","author":"B Prakken","year":"2011","unstructured":"Prakken B, Albani S, Martini A (2011) Juvenile idiopathic arthritis. Lancet 377(9783):2138\u20132149","journal-title":"Lancet"},{"issue":"5","key":"7340_CR34","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1080\/14397595.2020.1836788","volume":"31","author":"M Sezer","year":"2021","unstructured":"Sezer M, Aydin F, Kurt T, Tekgoz N, Tekin ZE, Karagol C et al (2021) Prediction of inactive disease and relapse in oligoarticular juvenile idiopathic arthritis. Mod Rheumatol 31(5):1025\u20131030","journal-title":"Mod Rheumatol"},{"issue":"4","key":"7340_CR35","doi-asserted-by":"publisher","first-page":"602","DOI":"10.46497\/ArchRheumatol.2023.10035","volume":"38","author":"R \u0130\u015fg\u00fcder","year":"2023","unstructured":"\u0130\u015fg\u00fcder R, K\u0131z\u0131lda\u011f Z, Torun R, Ayd\u0131n T, Makay B, \u00dcnsal E (2023) Risk of flare in juvenile idiopathic arthritis: is it related to the methotrexate treatment strategy or patient characteristics? Arch Rheumatol 38(4):602","journal-title":"Arch Rheumatol"},{"issue":"8","key":"7340_CR36","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1002\/art.42113","volume":"74","author":"JJ Lee","year":"2022","unstructured":"Lee JJ, Eng SW, Guzman J, Duffy CM, Tucker LB, Oen K et al (2022) A comparison of International League of Associations for Rheumatology and Pediatric Rheumatology International Trials Organization Classification Systems for juvenile idiopathic arthritis among children in a Canadian arthritis cohort. Arthritis Rheumatol 74(8):1409\u20131419","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"7340_CR37","first-page":"1864","volume":"9","author":"S Guerriero","year":"2022","unstructured":"Guerriero S, Palmieri R, Craig F, La Torre F, Albano V, Alessio G et al (2022) Psychological effects and quality of life in parents and children with Jia-associated uveitis. Children (Basel) 9(12):1864","journal-title":"Children (Basel)"},{"issue":"6","key":"7340_CR38","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3109\/09273948.2013.815785","volume":"21","author":"AT Vitale","year":"2013","unstructured":"Vitale AT, Graham E, de Boer JH (2013) Juvenile idiopathic arthritis-associated uveitis: clinical features and complications, risk factors for severe course, and visual outcome. Ocul Immunol Inflamm 21(6):478\u2013485","journal-title":"Ocul Immunol Inflamm"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07340-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07340-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07340-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T08:24:31Z","timestamp":1740558271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07340-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["7340"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07340-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"assertion":[{"value":"7 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}